Skip to main content


Figure 1 | BMC Musculoskeletal Disorders

Figure 1

From: Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study

Figure 1

Changes Over Time in the Mean 28-joint Disease Activity Score (DAS28). Mean change (95% confidence intervals [CI]) in DAS28 in patients receiving adalimumab 40 mg administered subcutaneously every other week with concomitant standard antirheumatic therapy. A.) All randomized patients. The mean DAS28 at Weeks 4, 8, and 12 were significantly lower than the mean DAS28 at baseline (P < 0.001). B.) Subgroup analysis of randomized patients on the basis of experience with biological DMARD (BDMARD) therapy. The mean DAS28 at Weeks 8 and 12 was significantly lower in BDMARD-naïve patients than in patients who experienced prior BDMARD therapy (P < 0.05).

Back to article page